LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $113,281 | -30.7% | 96,000 | -17.2% | 0.00% | – |
Q2 2023 | $163,561 | -16.1% | 116,000 | -10.8% | 0.00% | – |
Q1 2023 | $195,062 | +10.7% | 130,041 | -13.6% | 0.00% | – |
Q4 2022 | $176,150 | -17.7% | 150,555 | -20.5% | 0.00% | – |
Q3 2022 | $214,000 | -43.4% | 189,320 | -20.9% | 0.00% | – |
Q2 2022 | $378,000 | +56.2% | 239,320 | +52.6% | 0.00% | – |
Q1 2022 | $242,000 | -10.0% | 156,830 | +42.8% | 0.00% | – |
Q4 2021 | $269,000 | +21.7% | 109,791 | +25.4% | 0.00% | – |
Q3 2021 | $221,000 | +28.5% | 87,580 | +45.0% | 0.00% | – |
Q2 2021 | $172,000 | +53.6% | 60,380 | +26.8% | 0.00% | – |
Q1 2021 | $112,000 | +154.5% | 47,634 | +90.0% | 0.00% | – |
Q4 2020 | $44,000 | +91.3% | 25,073 | +4.2% | 0.00% | – |
Q3 2020 | $23,000 | +4.5% | 24,059 | -6.2% | 0.00% | – |
Q2 2020 | $22,000 | +69.2% | 25,649 | +64.2% | 0.00% | – |
Q1 2020 | $13,000 | -13.3% | 15,625 | -9.8% | 0.00% | – |
Q4 2019 | $15,000 | -11.8% | 17,314 | -2.2% | 0.00% | – |
Q3 2019 | $17,000 | – | 17,702 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Defender Capital, LLC. | 4,735,990 | $8,335,000 | 3.63% |
BROADWOOD CAPITAL INC | 34,005,379 | $59,849,000 | 3.55% |
Prescott General Partners LLC | 1,851,851 | $3,259,000 | 0.14% |
Strategic Wealth Investment Group, LLC | 66,917 | $118,000 | 0.07% |
Laidlaw Wealth Management LLC | 170,658 | $300,000 | 0.06% |
Humankind Investments LLC | 26,737 | $47,000 | 0.05% |
DAFNA Capital Management LLC | 80,000 | $141,000 | 0.04% |
Beirne Wealth Consulting Services, LLC | 45,000 | $79,000 | 0.04% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 680,839 | $1,198,000 | 0.02% |
Allegheny Financial Group LTD | 20,000 | $35,000 | 0.02% |